Skip to the page content
Your donations
Passes our checks

Addario Lung Cancer Medical Institute

EIN 26-1721868 · San Carlos, CA

Public records show a registered, tax-exempt organization in good standing.

LegitimacyPassesRegistration and standingFinancial healthGood71 out of 100GovernanceGood80 out of 100Impact evidenceDescribes programsHow well its results are evidenced

What it says it does

The Addario Lung Cancer Medical Institute ALCMI is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients.

Income
$1.9 million
Spending
$1.6 million
Spent on programs
85%
Reserves
1.2 months of spending
Largest source of income
donations and private grants, 82%
Employees
2
Highest pay
$230,871, sr. dir. clinical operations

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Good: 71 out of 100. Higher than 33% of charities in its peer group (medical research, $1m to $10m).

  • Reserves

    10 of 35

    Spendable reserves would cover 1.2 months of spending.

  • Debt

    16 of 20

    It owes 25% of what it owns.

  • Living within its means

    15 of 15

    Income exceeded spending by 17% of income.

  • Income trend

    15 of 15

    Income rose 23% on the year before.

  • Spending floor

    15 of 15

    85% of spending went to programs and raising each dollar of donations cost 4 cents.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Good: 80 out of 100. Higher than 30% of charities in its peer group (medical research, $1m to $10m).

  • Independent board

    25 of 25

    7 of 7 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    8 of 8

    Has a written whistleblower policy.

  • Record keeping policy

    7 of 7

    Has a written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    10 of 10

    Gave the board a copy of this return before filing it.

  • Pay set independently

    0 of 5

    Reports no independent review process for its chief executive's pay.

  • Independent check of accounts

    0 of 15

    Its accounts were not audited or reviewed by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (1)
  1. $1.3 million spent. Research - The Addario Lung Cancer Medical Institute (ALCMI) is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. ALCMI is a patient-founded, patient-focused research consortium. Its goal is to make lung cancer a chronically managed disease. ALCMI was created in 2008 to enable the collection and analysis of tissue and blood samples which are essential to research and to the development of individually tailored (and more effective) therapies. ALCMI is also a comprehensively contracted consortium with shared infrastructures (standardized contracts, data systems and biorepositories) and centrally coordinated scientific planning. Cont'd. at Schedule O (Cont'd. from page 2) ALCMI's researchers are pooling their knowledge, specimens and data in order to improve the understanding of the molecular bases of lung cancer and to accelerate the development and delivery of much more effective, targeted drugs and treatments tailored to individual patient types. ALCMI has developed, conducted, and published a number of innovative research studies that would otherwise not have existed: 1) CASTLE: a prospective, longitudinal, multi-center study with serial biobanked advanced stage lung cancer specimens that are also annotated with clinical/molecular data. 2) INHERIT EGFR T790M: a prospective study on germline biology in high-risk families; to identify specific inherited genetic markers indicating risk of developing lung cancer. 3) Genomics of Young Lung Cancer (GoYLC): a prospectively performed comprehensive genomic profiling to determine whether young lung cancers harbor a distinctive spectrum of genetic mutations, and therefore unique treatment strategies (peer-reviewed paper published in 2021, Journal of Thoracic Oncology). Other studies in progress are 4) Epidemiology of Young Lung Cancer (EoYLC): a remote decentralized survey study designed to identify lifestyle, environmental, and family/genetic risk factors associated with the development of lung cancer under the age of 50, and any possible connection to specific cancer-driving mutations. Data from this trial has now been presented at several national and international cancer conferences. The sponsor-funder of this trial has closed enrollment, and results from this trial have recently been submitted for feature at the 2026 American Academy of Cancer Research (AACR) conference. Plans are also to submit results to the 2026 World Conference Lung Cancer (Sept, Seoul). 5) SPACEWALK: a study to investigate the relationship between specific ALK resistance mutations and specific next generation ALK TKI therapies received before progression. The results of this trial were published in the Journal of Thoracic Oncology. 6) BEACON-LUNG: a multicenter study collecting serum, plasma, tissue, and CT images from patients receiving pembrolizumab or pembrolizumab plus carboplatin-based chemotherapy to help identify patients who may benefit from a more aggressive triplet treatment regimen. This test utilizes mass spectrometry with machine learning and was developed by Biodesix, Inc. to classify patients as responders or non-responders, which could help identify patients who may benefit from a triplet treatment regimen. This trial was closed prematurely by the sponsor-funder. 7) ENIGMA+: a remote decentralized study collecting tissue and sputum specimens and clinical outcome data across patients diagnosed with ALK+ mutation NSCLC. ALCMI recently achieved the enrollment goal for this study. 8) SPARK: a remote decentralized study collecting blood specimens and clinical outcome data across patients diagnosed with KRAS mutation NSCLC. The sponsor-funder of this trial has closed enrollment, and results from this trial have recently been submitted for feature at the 2026 American Academy of Cancer Research (AACR) conference. 9) TURN-AROUND-TIME: a regional, community hospital-based project aimed at establishing de novo Next Generation Sequencing (NGS) testing in facilities that heretofore rely on external "send-out" lab testing, and a research trial to test the hypothesis that putting NGS data into the hands of treating oncologists sooner can improve downstream patient treatment outcomes. 10) INHERIT 2.0: a new prospective study on germline biology in high-risk families using a more advanced panel of biomarkers; to identify specific inherited genetic markers indicating risk of developing lung cancer. 11) SUCCEED: a pilot feasibility trial to determine the viability and barriers of enrolling patients diagnosed with Small Cell Lung cancer (SCLC) into a remote decentralized format study.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.

  3. Are donations tax-deductible? Passed.

    On the IRS list of organizations eligible to receive tax-deductible contributions.

    Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending December 2024.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since April 2008.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.